时间标签：数据日期 2026-11-03 · 生成时间 2026-11-03 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/31 – 2026/11/03 ｜ 情报发生日期 2026-11-03
证据级别：摘要级。本条依据 PubMed 结构化摘要与元数据撰写，付费墙全文未获取、未逐节核验，本站未做任何数值推算补全。
摘要（PubMed 原文节选）
INTRODUCTION: Treatment decisions in older patients with mature B-cell lymphoproliferative disorders (MBLD) are frequently guided by chronological age and comorbidity burden, although their ability to predict clinically relevant outcomes remains uncertain. METHODS: We conducted a retrospective real-world study including 172 patients with MBLD between 2016 and 2021, assessing the association of age and comorbidity burden (standardised using the Cumulative Illness Rating Scale for Geriatrics, CIRS-G score) with treatment intensity, toxicity, and clinical outcomes. RESULTS: Treatment intensity decreased significantly with both age (p = 0.003) and CIRS-G score (p < 0.001). However, neither age n…
对本项目的价值
参考价值：属「衰弱 / 肌少症功能结局」方向；干预策略与临床试验栏目可用作本项目文献库与综述素材。 ｜ 价值分 1.7/5（★★☆☆☆）
全文不可及原因
无 PMCID 且 OpenAlex / Unpaywall 未提供可下载 OA PDF
原文题录
- 中文题名：成熟 B 细胞淋巴增殖性疾病中的年龄、共病负担与治疗结局：真实世界研究
- 英文标题：Age, Comorbidity Burden and Treatment Outcomes in Mature B-Cell Lymphoproliferative Disorders: A Real-World Study.
- 期刊与标识：Cancer Med · PMID 42968459 · DOI 10.1002/cam4.72460 · EDAT 2026-11-02